Frequently Asked Questions
The market is segmented based on , By Disease Type (Neurological Disorders, Immunological Disorders, Hematology Diseases, Endocrine and Metabolism Diseases, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders (CVDs), Dermatology Disease, Others), Technology (Next-Generation Sequencing (NGS), Array Technology, PCR-based Testing, FISH, Sanger Sequencing, Karyotyping), Specialty (Molecular Genetic Tests, Chromosomal Genetic Tests, Biochemical Genetic Tests), End Use (Research Laboratories and CROs, Diagnostic Centers, Hospitals and Clinics) – Industry Trends and Forecast to 2029.
.
The Global Rare Disease Genetic Testing Market size was valued at USD 785.80 USD Billion in 2021.
The Global Rare Disease Genetic Testing Market is projected to grow at a CAGR of 12.26% during the forecast period of 2022 to 2029.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
